Spreadsheet: 22115e28-a8a1-45bf-a920-26b521b6bbbc
Sheet: Table S5

Pathways in human PSD as compared with human genome |  |  |  |  |  |  |  | Pathways in mouse PSD as compared with human genome
[NAME] | Homo sapiens genes | Observed | Expected | (over/under) | P-value | Corrected P-value |  | [NAME] | Observed | Expected | (over/under) | P-value | Corrected P-value
Unclassified | 17270 | 121 | 148.32 | - | 3.55e-08 | 5.467e-06 |  | Ionotropic glutamate receptor pathway | 15 | .73 | + | 2.65e-15 | 4.081e-13
[NAME] | 15 | 4 | .13 | + | 1e-05 | 0.0007700000000000001 |  | Metabotropic glutamate receptor group III pathway | 11 | .95 | + | 5.19e-09 | 7.9926e-07
Parkinson disease | 97 | 7 | .83 | + | 2.43e-05 | 0.0012474 |  | Metabotropic glutamate receptor group II pathway | 7 | .64 | + | 4.67e-06 | 0.00071918
Axon guidance mediated by semaphorins | 37 | 4 | .32 | + | 0.00032 | 0.01232 |  | Synaptic_vesicle_trafficking | 6 | .50 | + | 1.41e-05 | 0.0021714
Apoptosis signaling pathway | 119 | 6 | 1.02 | + | 0.000626 | 0.0192808 |  | Metabotropic glutamate receptor group I pathway | 5 | .35 | + | 3.34e-05 | 0.0051436
Glycolysis | 24 | 3 | .21 | + | 0.00123 | 0.03157 |  | GABA-B_receptor_II_signaling | 5 | .54 | + | 0.000247 | 0.038038
De novo purine biosynthesis | 33 | 3 | .28 | + | 0.00303 | 0.06666000000000001 |  | Unclassified | 214 | 235.05 | - | 0.000269 | 0.041426
EGF receptor signaling pathway | 130 | 5 | 1.12 | + | 0.00558 | 0.107415 |  | [NAME] signaling pathway-Gq alpha and Go alpha mediated pathway | 8 | 1.82 | + | 0.000574 | 0.08839599999999999
Integrin signalling pathway | 196 | 6 | 1.68 | + | 0.0073 | 0.1249111111111111 |  | Thyrotropin-releasing hormone receptor signaling pathway | 5 | .84 | + | 0.00173 | 0.26642
TCA cycle | 16 | 2 | .14 | + | 0.00858 | 0.132132 |  | Endothelin signaling pathway | 5 | 1.20 | + | 0.00753 | 1
Cytoskeletal regulation by Rho GTPase | 98 | 4 | .84 | + | 0.0105 | 0.1452 |  | [NAME] signaling pathway-Gi alpha and [NAME] alpha mediated pathway | 7 | 2.23 | + | 0.00775 | 1
5-Hydroxytryptamine degredation | 19 | 2 | .16 | + | 0.0119 | 0.1452 |  | Muscarinic acetylcholine receptor 2 and 4 signaling pathway | 4 | .84 | + | 0.0107 | 1
Toll receptor signaling pathway | 56 | 3 | .48 | + | 0.0128 | 0.1452 |  | Beta2 adrenergic receptor signaling pathway | 3 | .60 | + | 0.0229 | 1
Huntington disease | 161 | 5 | 1.38 | + | 0.0132 | 0.1452 |  | [NAME] adrenergic receptor signaling pathway | 3 | .60 | + | 0.0229 | 1
Ubiquitin proteasome pathway | 69 | 3 | .59 | + | 0.0222 | 0.2065411764705882 |  | Alpha adrenergic receptor signaling pathway | 2 | .31 | + | 0.0398 | 1
VEGF signaling pathway | 69 | 3 | .59 | + | 0.0222 | 0.2065411764705882 |  | Endogenous_cannabinoid_signaling | 2 | .33 | + | 0.0429 | 1
FGF signaling pathway | 124 | 4 | 1.06 | + | 0.0228 | 0.2065411764705882 |  | Nicotinic acetylcholine receptor signaling pathway | 4 | 1.31 | + | 0.0433 | 1
Phenylalanine biosynthesis | 3 | 1 | .03 | + | 0.0254 | 0.2173111111111111 |  | Cytoskeletal regulation by Rho GTPase | 4 | 1.33 | + | 0.0461 | 1
Tyrosine biosynthesis | 4 | 1 | .03 | + | 0.0338 | 0.2739578947368421 |  | Beta3 adrenergic receptor signaling pathway | 2 | .35 | + | 0.0495 | 1
Synaptic_vesicle_trafficking | 37 | 2 | .32 | + | 0.0408 | 0.308 |  | Muscarinic acetylcholine receptor 1 and 3 signaling pathway | 3 | .83 | + | 0.0516 | 1
Serine glycine biosynthesis | 5 | 1 | .04 | + | 0.042 | 0.308 |  | Proline biosynthesis | 1 | .05 | + | 0.053 | 1
Asparagine and aspartate biosynthesis | 5 | 1 | .04 | + | 0.042 | 0.308 |  | Hedgehog signaling pathway | 2 | .38 | + | 0.0564 | 1
Angiogenesis | 176 | 4 | 1.51 | + | 0.0663 | 0.4260666666666666 |  | Cortocotropin releasing factor receptor signaling pathway | 2 | .41 | + | 0.0637 | 1
Pentose phosphate pathway | 8 | 1 | .07 | + | 0.0664 | 0.4260666666666666 |  | 5HT4 type receptor mediated signaling pathway | 2 | .42 | + | 0.0674 | 1
Arginine biosynthesis | 8 | 1 | .07 | + | 0.0664 | 0.4260666666666666 |  | Huntington disease | 5 | 2.19 | + | 0.0708 | 1
Phenylethylamine degradation | 10 | 1 | .09 | + | 0.0823 | 0.4874692307692307 |  | Adrenaline and noradrenaline biosynthesis | 2 | .44 | + | 0.0712 | 1
Inflammation mediated by chemokine and cytokine signaling pathway | 272 | 5 | 2.34 | + | 0.0866 | 0.4939407407407407 |  | EGF receptor signaling pathway | 4 | 1.77 | + | 0.103 | 1
[NAME] | 75 | 2 | .64 | + | 0.136 | 0.7480000000000001 |  | Integrin signalling pathway | 5 | 2.67 | + | 0.131 | 1
Dopamine receptor mediated signaling pathway | 80 | 2 | .69 | + | 0.151 | 0.8018620689655171 |  | Notch signaling pathway | 2 | .64 | + | 0.135 | 1
T cell activation | 88 | 2 | .76 | + | 0.175 | 0.8983333333333333 |  | Transcription regulation by bZIP transcription factor | 2 | .73 | + | 0.168 | 1
Interferon-gamma signaling pathway | 29 | 1 | .25 | + | 0.221 | 1 |  | TCA cycle | 1 | .22 | + | 0.196 | 1
Wnt signaling pathway | 318 | 1 | 2.73 | - | 0.241 | 1 |  | Oxytocin receptor mediated signaling pathway | 2 | .82 | + | 0.197 | 1
Insulin/IGF pathway-mitogen activated protein kinase kinase/MAP kinase cascade | 34 | 1 | .29 | + | 0.253 | 1 |  | 5HT3 type receptor mediated signaling pathway | 1 | .24 | + | 0.217 | 1
FAS signaling pathway | 36 | 1 | .31 | + | 0.266 | 1 |  | VEGF signaling pathway | 2 | .94 | + | 0.242 | 1
Alzheimer disease-presenilin pathway | 122 | 2 | 1.05 | + | 0.282 | 1 |  | 5HT2 type receptor mediated signaling pathway | 2 | .94 | + | 0.242 | 1
[NAME]-stimulated signaling through G proteins and beta-arrestin | 40 | 1 | .34 | + | 0.291 | 1 |  | [NAME] | 2 | 1.02 | + | 0.272 | 1
[NAME] signaling pathway-Gq alpha and Go alpha mediated pathway | 134 | 0 | 1.15 | - | 0.315 | 1 |  | Histamine H2 receptor mediated signaling pathway | 1 | .34 | + | 0.289 | 1
p38 MAPK pathway | 46 | 1 | .40 | + | 0.327 | 1 |  | Axon guidance mediated by Slit/Robo | 1 | .34 | + | 0.289 | 1
PDGF signaling pathway | 148 | 2 | 1.27 | + | 0.363 | 1 |  | Dopamine receptor mediated signaling pathway | 2 | 1.09 | + | 0.297 | 1
TGF-beta signaling pathway | 149 | 2 | 1.28 | + | 0.366 | 1 |  | Insulin/IGF pathway-protein kinase B signaling cascade | 0 | 1.20 | - | 0.301 | 1
Alzheimer disease-amyloid secretase pathway | 67 | 1 | .58 | + | 0.438 | 1 |  | Inflammation mediated by chemokine and cytokine signaling pathway | 5 | 3.70 | + | 0.313 | 1
B cell activation | 73 | 1 | .63 | + | 0.466 | 1 |  | Cadherin signaling pathway | 3 | 1.99 | + | 0.32 | 1
Insulin/IGF pathway-protein kinase B signaling cascade | 88 | 0 | .76 | - | 0.469 | 1 |  | TGF-beta signaling pathway | 3 | 2.03 | + | 0.331 | 1
Endothelin signaling pathway | 88 | 1 | .76 | + | 0.531 | 1 |  | Opioid prodynorphin pathway | 1 | .42 | + | 0.344 | 1
Metabotropic glutamate receptor group III pathway | 70 | 0 | .60 | - | 0.548 | 1 |  | Opioid proenkephalin pathway | 1 | .42 | + | 0.344 | 1
5HT2 type receptor mediated signaling pathway | 69 | 0 | .59 | - | 0.552 | 1 |  | Opioid proopiomelanocortin pathway | 1 | .44 | + | 0.353 | 1
Nicotinic acetylcholine receptor signaling pathway | 96 | 1 | .82 | + | 0.562 | 1 |  | Interleukin signaling pathway | 1 | 2.16 | - | 0.362 | 1
Thyrotropin-releasing hormone receptor signaling pathway | 62 | 0 | .53 | - | 0.587 | 1 |  | Wnt signaling pathway | 3 | 4.33 | - | 0.37 | 1
Muscarinic acetylcholine receptor 2 and 4 signaling pathway | 62 | 0 | .53 | - | 0.587 | 1 |  | Axon guidance mediated by netrin | 1 | .48 | + | 0.379 | 1
[NAME] signaling pathway-Gi alpha and [NAME] alpha mediated pathway | 164 | 1 | 1.41 | - | 0.588 | 1 |  | Parkinson disease | 2 | 1.32 | + | 0.381 | 1
Muscarinic acetylcholine receptor 1 and 3 signaling pathway | 61 | 0 | .52 | - | 0.592 | 1 |  | Ubiquitin proteasome pathway | 0 | .94 | - | 0.39 | 1
Oxytocin receptor mediated signaling pathway | 60 | 0 | .52 | - | 0.597 | 1 |  | PDGF signaling pathway | 1 | 2.01 | - | 0.401 | 1
Interleukin signaling pathway | 159 | 1 | 1.37 | - | 0.603 | 1 |  | Alzheimer disease-amyloid secretase pathway | 0 | .91 | - | 0.401 | 1
Oxidative stress response | 56 | 0 | .48 | - | 0.618 | 1 |  | [NAME] signaling pathway-rod outer segment phototransduction | 1 | .53 | + | 0.412 | 1
p53 pathway | 114 | 1 | .98 | + | 0.625 | 1 |  | 5HT1 type receptor mediated signaling pathway | 1 | .60 | + | 0.451 | 1
Transcription regulation by bZIP transcription factor | 54 | 0 | .46 | - | 0.629 | 1 |  | Toll receptor signaling pathway | 0 | .76 | - | 0.466 | 1
Ionotropic glutamate receptor pathway | 54 | 0 | .46 | - | 0.629 | 1 |  | Oxidative stress response | 0 | .76 | - | 0.466 | 1
p53 pathway feedback loops 2 | 52 | 0 | .45 | - | 0.639 | 1 |  | PI3 kinase pathway | 2 | 1.59 | + | 0.473 | 1
Cadherin signaling pathway | 146 | 1 | 1.25 | - | 0.643 | 1 |  | FGF signaling pathway | 2 | 1.69 | + | 0.504 | 1
Blood coagulation | 48 | 0 | .41 | - | 0.662 | 1 |  | Alzheimer disease-presenilin pathway | 1 | 1.66 | - | 0.505 | 1
Notch signaling pathway | 47 | 0 | .40 | - | 0.668 | 1 |  | p53 pathway feedback loops 2 | 1 | .71 | + | 0.508 | 1
Metabotropic glutamate receptor group II pathway | 47 | 0 | .40 | - | 0.668 | 1 |  | Apoptosis signaling pathway | 1 | 1.62 | - | 0.518 | 1
Histamine H1 receptor mediated signaling pathway | 47 | 0 | .40 | - | 0.668 | 1 |  | Blood coagulation | 0 | .65 | - | 0.52 | 1
Beta2 adrenergic receptor signaling pathway | 44 | 0 | .38 | - | 0.685 | 1 |  | Histamine H1 receptor mediated signaling pathway | 0 | .64 | - | 0.527 | 1
[NAME] adrenergic receptor signaling pathway | 44 | 0 | .38 | - | 0.685 | 1 |  | p38 MAPK pathway | 0 | .63 | - | 0.534 | 1
5HT1 type receptor mediated signaling pathway | 44 | 0 | .38 | - | 0.685 | 1 |  | p53 pathway | 1 | 1.55 | - | 0.54 | 1
GABA-B_receptor_II_signaling | 40 | 0 | .34 | - | 0.709 | 1 |  | Angiogenesis | 2 | 2.40 | - | 0.57 | 1
[NAME] signaling pathway-rod outer segment phototransduction | 39 | 0 | .33 | - | 0.715 | 1 |  | [NAME]-stimulated signaling through G proteins and beta-arrestin | 0 | .54 | - | 0.58 | 1
General transcription regulation | 37 | 0 | .32 | - | 0.728 | 1 |  | Axon guidance mediated by semaphorins | 0 | .50 | - | 0.604 | 1
PI3 kinase pathway | 117 | 1 | 1.00 | - | 0.734 | 1 |  | General transcription regulation | 0 | .50 | - | 0.604 | 1
Axon guidance mediated by netrin | 35 | 0 | .30 | - | 0.74 | 1 |  | FAS signaling pathway | 0 | .49 | - | 0.612 | 1
Enkephalin release | 33 | 0 | .28 | - | 0.753 | 1 |  | Insulin/IGF pathway-mitogen activated protein kinase kinase/MAP kinase cascade | 0 | .46 | - | 0.629 | 1
Adrenaline and noradrenaline biosynthesis | 32 | 0 | .27 | - | 0.76 | 1 |  | B cell activation | 1 | .99 | + | 0.63 | 1
Opioid proopiomelanocortin pathway | 32 | 0 | .27 | - | 0.76 | 1 |  | De novo purine biosynthesis | 0 | .45 | - | 0.638 | 1
Hypoxia response via HIF activation | 32 | 0 | .27 | - | 0.76 | 1 |  | Enkephalin release | 0 | .45 | - | 0.638 | 1
Opioid prodynorphin pathway | 31 | 0 | .27 | - | 0.766 | 1 |  | Hypoxia response via HIF activation | 0 | .44 | - | 0.647 | 1
Opioid proenkephalin pathway | 31 | 0 | .27 | - | 0.766 | 1 |  | T cell activation | 1 | 1.20 | - | 0.663 | 1
5HT4 type receptor mediated signaling pathway | 31 | 0 | .27 | - | 0.766 | 1 |  | Interferon-gamma signaling pathway | 0 | .39 | - | 0.674 | 1
Cortocotropin releasing factor receptor signaling pathway | 30 | 0 | .26 | - | 0.773 | 1 |  | Nicotine degradation | 0 | .34 | - | 0.711 | 1
Hedgehog signaling pathway | 28 | 0 | .24 | - | 0.786 | 1 |  | p53 pathway by glucose deprivation | 0 | .34 | - | 0.711 | 1
Metabotropic glutamate receptor group I pathway | 26 | 0 | .22 | - | 0.8 | 1 |  | Glycolysis | 0 | .33 | - | 0.721 | 1
Beta3 adrenergic receptor signaling pathway | 26 | 0 | .22 | - | 0.8 | 1 |  | Cell cycle | 0 | .30 | - | 0.741 | 1
Nicotine degradation | 25 | 0 | .21 | - | 0.807 | 1 |  | DNA replication | 0 | .29 | - | 0.751 | 1
p53 pathway by glucose deprivation | 25 | 0 | .21 | - | 0.807 | 1 |  | General transcription by [NAME] polymerase I | 0 | .27 | - | 0.762 | 1
Histamine H2 receptor mediated signaling pathway | 25 | 0 | .21 | - | 0.807 | 1 |  | 5-Hydroxytryptamine degredation | 0 | .26 | - | 0.772 | 1
Axon guidance mediated by Slit/Robo | 25 | 0 | .21 | - | 0.807 | 1 |  | Androgen/estrogene/progesterone biosynthesis | 0 | .26 | - | 0.772 | 1
Endogenous_cannabinoid_signaling | 24 | 0 | .21 | - | 0.814 | 1 |  | De novo pyrmidine ribonucleotides biosythesis | 0 | .24 | - | 0.783 | 1
Alpha adrenergic receptor signaling pathway | 23 | 0 | .20 | - | 0.821 | 1 |  | Plasminogen activating cascade | 0 | .24 | - | 0.783 | 1
Cell cycle | 22 | 0 | .19 | - | 0.828 | 1 |  | De novo pyrimidine deoxyribonucleotide biosynthesis | 0 | .24 | - | 0.783 | 1
DNA replication | 21 | 0 | .18 | - | 0.835 | 1 |  | JAK/STAT signaling pathway | 0 | .23 | - | 0.793 | 1
General transcription by [NAME] polymerase I | 20 | 0 | .17 | - | 0.842 | 1 |  | [NAME] | 0 | .20 | - | 0.815 | 1
Androgen/estrogene/progesterone biosynthesis | 19 | 0 | .16 | - | 0.849 | 1 |  | Salvage pyrimidine ribonucleotides | 0 | .19 | - | 0.826 | 1
De novo pyrmidine ribonucleotides biosythesis | 18 | 0 | .15 | - | 0.857 | 1 |  | Pyruvate metabolism | 0 | .19 | - | 0.826 | 1
Plasminogen activating cascade | 18 | 0 | .15 | - | 0.857 | 1 |  | Heme biosynthesis | 0 | .18 | - | 0.838 | 1
De novo pyrimidine deoxyribonucleotide biosynthesis | 18 | 0 | .15 | - | 0.857 | 1 |  | Cholesterol biosynthesis | 0 | .18 | - | 0.838 | 1
5HT3 type receptor mediated signaling pathway | 18 | 0 | .15 | - | 0.857 | 1 |  | Fructose galactose metabolism | 0 | .16 | - | 0.849 | 1
JAK/STAT signaling pathway | 17 | 0 | .15 | - | 0.864 | 1 |  | Vitamin D metabolism and pathway | 0 | .16 | - | 0.849 | 1
Salvage pyrimidine ribonucleotides | 14 | 0 | .12 | - | 0.887 | 1 |  | [NAME] synthesis | 0 | .16 | - | 0.849 | 1
Pyruvate metabolism | 14 | 0 | .12 | - | 0.887 | 1 |  | Circadian clock system | 0 | .16 | - | 0.849 | 1
Heme biosynthesis | 13 | 0 | .11 | - | 0.894 | 1 |  | Phenylethylamine degradation | 0 | .14 | - | 0.873 | 1
Cholesterol biosynthesis | 13 | 0 | .11 | - | 0.894 | 1 |  | Formyltetrahydroformate biosynthesis | 0 | .14 | - | 0.873 | 1
Fructose galactose metabolism | 12 | 0 | .10 | - | 0.902 | 1 |  | mRNA splicing | 0 | .12 | - | 0.885 | 1
Vitamin D metabolism and pathway | 12 | 0 | .10 | - | 0.902 | 1 |  | Pentose phosphate pathway | 0 | .11 | - | 0.897 | 1
[NAME] synthesis | 12 | 0 | .10 | - | 0.902 | 1 |  | Arginine biosynthesis | 0 | .11 | - | 0.897 | 1
Circadian clock system | 12 | 0 | .10 | - | 0.902 | 1 |  | Adenine and hypoxanthine salvage pathway | 0 | .11 | - | 0.897 | 1
Formyltetrahydroformate biosynthesis | 10 | 0 | .09 | - | 0.918 | 1 |  | ATP synthesis | 0 | .11 | - | 0.897 | 1
mRNA splicing | 9 | 0 | .08 | - | 0.926 | 1 |  | 2-arachidonoylglycerol biosynthesis | 0 | .10 | - | 0.909 | 1
Adenine and hypoxanthine salvage pathway | 8 | 0 | .07 | - | 0.934 | 1 |  | N-acetylglucosamine metabolism | 0 | .10 | - | 0.909 | 1
ATP synthesis | 8 | 0 | .07 | - | 0.934 | 1 |  | Mannose metabolism | 0 | .10 | - | 0.909 | 1
2-arachidonoylglycerol biosynthesis | 7 | 0 | .06 | - | 0.942 | 1 |  | P53 pathway feedback loops 1 | 0 | .10 | - | 0.909 | 1
N-acetylglucosamine metabolism | 7 | 0 | .06 | - | 0.942 | 1 |  | Purine metabolism | 0 | .08 | - | 0.922 | 1
Mannose metabolism | 7 | 0 | .06 | - | 0.942 | 1 |  | Folate biosynthesis | 0 | .08 | - | 0.922 | 1
P53 pathway feedback loops 1 | 7 | 0 | .06 | - | 0.942 | 1 |  | Coenzyme A biosynthesis | 0 | .08 | - | 0.922 | 1
Purine metabolism | 6 | 0 | .05 | - | 0.95 | 1 |  | Gamma-aminobutyric acid synthesis | 0 | .08 | - | 0.922 | 1
Folate biosynthesis | 6 | 0 | .05 | - | 0.95 | 1 |  | 5-Hydroxytryptamine biosynthesis | 0 | .08 | - | 0.922 | 1
Coenzyme A biosynthesis | 6 | 0 | .05 | - | 0.95 | 1 |  | Serine glycine biosynthesis | 0 | .07 | - | 0.934 | 1
Gamma-aminobutyric acid synthesis | 6 | 0 | .05 | - | 0.95 | 1 |  | Asparagine and aspartate biosynthesis | 0 | .07 | - | 0.934 | 1
5-Hydroxytryptamine biosynthesis | 6 | 0 | .05 | - | 0.95 | 1 |  | Tyrosine biosynthesis | 0 | .05 | - | 0.947 | 1
Xanthine and guanine salvage pathway | 4 | 0 | .03 | - | 0.966 | 1 |  | Xanthine and guanine salvage pathway | 0 | .05 | - | 0.947 | 1
Salvage pyrimidine deoxyribonucleotides | 4 | 0 | .03 | - | 0.966 | 1 |  | Salvage pyrimidine deoxyribonucleotides | 0 | .05 | - | 0.947 | 1
Proline biosynthesis | 4 | 0 | .03 | - | 0.966 | 1 |  | O-antigen biosynthesis | 0 | .05 | - | 0.947 | 1
O-antigen biosynthesis | 4 | 0 | .03 | - | 0.966 | 1 |  | Methylmalonyl pathway | 0 | .05 | - | 0.947 | 1
Methylmalonyl pathway | 4 | 0 | .03 | - | 0.966 | 1 |  | Methylcitrate cycle | 0 | .05 | - | 0.947 | 1
Methylcitrate cycle | 4 | 0 | .03 | - | 0.966 | 1 |  | Glutamine glutamate conversion | 0 | .05 | - | 0.947 | 1
Glutamine glutamate conversion | 4 | 0 | .03 | - | 0.966 | 1 |  | Ascorbate degradation | 0 | .05 | - | 0.947 | 1
Ascorbate degradation | 4 | 0 | .03 | - | 0.966 | 1 |  | Phenylalanine biosynthesis | 0 | .04 | - | 0.96 | 1
[NAME] metabolism | 3 | 0 | .03 | - | 0.975 | 1 |  | [NAME] metabolism | 0 | .04 | - | 0.96 | 1
[NAME] biosynthesis | 3 | 0 | .03 | - | 0.975 | 1 |  | [NAME] biosynthesis | 0 | .04 | - | 0.96 | 1
S adenosyl methionine biosynthesis | 3 | 0 | .03 | - | 0.975 | 1 |  | S adenosyl methionine biosynthesis | 0 | .04 | - | 0.96 | 1
Ornithine degradation | 3 | 0 | .03 | - | 0.975 | 1 |  | Ornithine degradation | 0 | .04 | - | 0.96 | 1
Isoleucine biosynthesis | 3 | 0 | .03 | - | 0.975 | 1 |  | Isoleucine biosynthesis | 0 | .04 | - | 0.96 | 1
Acetate utilization | 3 | 0 | .03 | - | 0.975 | 1 |  | Acetate utilization | 0 | .04 | - | 0.96 | 1
Threonine biosynthesis | 2 | 0 | .02 | - | 0.983 | 1 |  | Threonine biosynthesis | 0 | .03 | - | 0.973 | 1
Thiamine metabolism | 2 | 0 | .02 | - | 0.983 | 1 |  | Thiamine metabolism | 0 | .03 | - | 0.973 | 1
Sulfate assimilation | 2 | 0 | .02 | - | 0.983 | 1 |  | Sulfate assimilation | 0 | .03 | - | 0.973 | 1
Succinate to proprionate conversion | 2 | 0 | .02 | - | 0.983 | 1 |  | Succinate to proprionate conversion | 0 | .03 | - | 0.973 | 1
Pyridoxal phosphate salvage pathway | 2 | 0 | .02 | - | 0.983 | 1 |  | Pyridoxal phosphate salvage pathway | 0 | .03 | - | 0.973 | 1
PLP biosynthesis | 2 | 0 | .02 | - | 0.983 | 1 |  | PLP biosynthesis | 0 | .03 | - | 0.973 | 1
Lysine biosynthesis | 2 | 0 | .02 | - | 0.983 | 1 |  | Lysine biosynthesis | 0 | .03 | - | 0.973 | 1
Lipoate_biosynthesis | 2 | 0 | .02 | - | 0.983 | 1 |  | Lipoate_biosynthesis | 0 | .03 | - | 0.973 | 1
Leucine biosynthesis | 2 | 0 | .02 | - | 0.983 | 1 |  | Leucine biosynthesis | 0 | .03 | - | 0.973 | 1
Carnitine metabolism | 2 | 0 | .02 | - | 0.983 | 1 |  | Carnitine metabolism | 0 | .03 | - | 0.973 | 1
Carnitine and CoA metabolism | 2 | 0 | .02 | - | 0.983 | 1 |  | Carnitine and CoA metabolism | 0 | .03 | - | 0.973 | 1
Histamine synthesis | 2 | 0 | .02 | - | 0.983 | 1 |  | Histamine synthesis | 0 | .03 | - | 0.973 | 1
Aminobutyrate degradation | 2 | 0 | .02 | - | 0.983 | 1 |  | Aminobutyrate degradation | 0 | .03 | - | 0.973 | 1
Alanine biosynthesis | 2 | 0 | .02 | - | 0.983 | 1 |  | Alanine biosynthesis | 0 | .03 | - | 0.973 | 1
Triacylglycerol metabolism | 1 | 0 | .01 | - | 0.991 | 1 |  | Triacylglycerol metabolism | 0 | .01 | - | 0.986 | 1
Bupropion_degradation | 1 | 0 | .01 | - | 0.991 | 1 |  | Bupropion_degradation | 0 | .01 | - | 0.986 | 1
Anandamide_degradation | 1 | 0 | .01 | - | 0.991 | 1 |  | Anandamide_degradation | 0 | .01 | - | 0.986 | 1
[NAME] biosynthesis | 1 | 0 | .01 | - | 0.991 | 1 |  | [NAME] biosynthesis | 0 | .01 | - | 0.986 | 1
Flavin biosynthesis | 1 | 0 | .01 | - | 0.991 | 1 |  | Flavin biosynthesis | 0 | .01 | - | 0.986 | 1
Cysteine biosynthesis | 1 | 0 | .01 | - | 0.991 | 1 |  | Cysteine biosynthesis | 0 | .01 | - | 0.986 | 1
Cobalamin biosynthesis | 1 | 0 | .01 | - | 0.991 | 1 |  | Cobalamin biosynthesis | 0 | .01 | - | 0.986 | 1
Allantoin degradation | 1 | 0 | .01 | - | 0.991 | 1 |  | Allantoin degradation | 0 | .01 | - | 0.986 | 1
 |  |  |  |  |  | 1 |  |  |  |  |  |  | 1